Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs Virtu Financial Inc. Class A Common Stock (VIRT) Price & Performance

Kymera Therapeutics Inc. Common StockTrade
Virtu Financial Inc. Class A Common StockTrade

Price performance (Past 24H)

Key statistics

Kymera Therapeutics Inc. Common Stock vs Virtu Financial Inc. Class A Common Stock — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $106.9 (market cap $8.87B), while Virtu Financial Inc. Class A Common Stock trades at $55.56 (market cap $4.94B). The key difference: Kymera Therapeutics Inc. Common Stock is the larger of the two by market cap, and Virtu Financial Inc. Class A Common Stock pays a 1.72% dividend while Kymera Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and Virtu Financial Inc. Class A Common Stock for 6 Days on average.

KYMRVIRT
Market Cap
$8.87B$4.94B
Volume
779,1071,546,091
Sector
HealthFinancials
52-Week High
$127.31$67.93
52-Week Low
$55.80$32.53
Typical Hold Time
0 Days6 Days
Enterprise Value
$8.26B$14.65B
Dividend Yield
—1.72%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Kymera Therapeutics Inc. Common Stock

No Aura AI signal available yet.

Virtu Financial Inc. Class A Common Stock

VIRT trades at $55.94, down 1.46% today, with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with a P/E of 9.29, net income margin of 13.5%, and ROE of 31.65%. Recent expansion into Saudi Exchange block trading and consistent earnings outperformance support growth prospects. Analyst consensus price target is $63.00 with mixed ratings (38% buy, 46% hold).

VIRT presents a value opportunity with attractive valuation metrics and strong profitability, though technical indicators suggest near-term pressure. The company's market-making business demonstrates resilience with improving cash flow trends. Key risks include market volatility sensitivity and competitive pressures in financial services.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

KYMR
100% Buy0% Sell
Avg holding period · 0 Days
VIRT

No sentiment data available yet.

Top news

Latest headlines on both assets

About Kymera Therapeutics Inc. Common Stock

Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.

Read more on KYMR →

About Virtu Financial Inc. Class A Common Stock

Virtu Financial provides technology-enabled market-making and execution services. Its platforms help institutional, retail, and other market participants trade across global financial markets.

Read more on VIRT →